Hemogenyx Pharmaceuticals PLC Announces Publication of Prospectus

Rhea-AI Summary

Hemogenyx Pharmaceuticals (HOPHF) published a Prospectus for the admission of 116,982 new ordinary shares on conversion of convertible loan notes and 439,629 new ordinary shares on exercise of warrants (together 556,611 New Ordinary Shares) to the equity shares (transition) category of the FCA Official List and to trading on the Main Market of the London Stock Exchange.

Admission is expected to become effective and unconditional, and dealings in the New Ordinary Shares are expected to commence on 24 November 2025. The Prospectus is available at the company's registered office and online at https://hemogenyx.com, and will be submitted to the National Storage Mechanism for inspection.

Positive

• 556,611 New Ordinary Shares announced for Admission
• Admission expected to commence on 24 November 2025
• Prospectus available online at https://hemogenyx.com and via FCA storage

Negative

• Issuance of 556,611 New Ordinary Shares will increase the company’s share count
• Distribution limited by jurisdictions where release would violate applicable securities laws

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

LONDON, UK / ACCESS Newswire / November 19, 2025 / This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the "Prospectus") in its final form that is published by Hemogenyx Pharmaceuticals plc in connection with the admission of new ordinary shares in the capital of the Company (the "New Ordinary Shares") to listing in equity shares (transition) category of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") following conversion of certain convertible loan notes and exercise of certain warrants.

19 November 2025

Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Publication of Prospectus

The Company is pleased to announce today the publication of a Prospectus in relation to the admission of 116,982 new ordinary shares of 0.01 pence each to be issued upon conversion of convertible loan notes issued by the Company on 31 August 2025 (the "Convertible Loan NotesShares") and 439,629 new ordinary shares of 0.01 pence each to be issued following the exercise of certain of the warrants issued by the Company during 2025 (the "Warrant Shares") (together the "New Ordinary Shares") to listing in the equity shares (transition) category of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange (together, "Admission").

It is expected that Admission will become effective, and unconditional dealings in the New Ordinary Shares will commence on 24 November 2025.

The Prospectus will be available from the Company's registered office at 6 Heddon Street, London W1B 4BT, United Kingdom and online at https://hemogenyx.com (subject to applicable securities laws).

An electronic copy of the Prospectus will also be submitted to the National Storage Mechanism and should be available shortly for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

FAQ

What did Hemogenyx (HOPHF) announce on 19 November 2025 about a prospectus?

Hemogenyx published a Prospectus for the admission of 116,982 conversion shares and 439,629 warrant shares (total 556,611) to the FCA Official List and Main Market.

When will Hemogenyx (HOPHF) new ordinary shares start trading on the London Stock Exchange?

The company expects Admission to become effective and unconditional and trading to commence on 24 November 2025.

How many new ordinary shares will Hemogenyx (HOPHF) issue on conversion and warrants?

Hemogenyx will issue 116,982 shares on conversion of convertible loan notes and 439,629 shares on exercise of warrants, totaling 556,611.

Where can investors access the Hemogenyx (HOPHF) Prospectus?

The Prospectus is available at the company's registered office at 6 Heddon Street, London W1B 4BT and online at https://hemogenyx.com; an electronic copy will be on the FCA National Storage Mechanism.

Does the Hemogenyx (HOPHF) announcement include any trading or distribution restrictions?

Yes; the announcement states it is not for release or distribution in jurisdictions where doing so would violate applicable securities laws.